{"success":true,"data":{"pressRelease":{"id":"37392","rtpr_id":"nWkr3xzwHF","ticker":"ISAB","exchange":"","all_tickers":["ISAB"],"title":"Inhalation Sciences receives IRS order worth approximately EUR 117,000","author":"Cision","published_at":"2026-05-18T08:10:09.079Z","article_body":"Inhalation Sciences\nInhalation Sciences Sweden AB (ISAB) today announces that it has received an\nIRS (Inhalation Research Services) order valued at approximately EUR 117,000\n(approximately SEK 1.3 million) from a new customer.\n\nThe customer is a European-based pharmaceutical and biotechnology company with\nextensive experience in producing both generic and innovative medicines.\n\nISAB will use its PreciseInhale® platform technology to generate high-quality\npreclinical study data. The study will involve in vivo testing - meaning the\nresearch is conducted in living organisms - to evaluate how the inhaled\ncompound behaves under real biological conditions.\n\n\"We are pleased that such a leading pharmaceutical company has chosen to\npartner with us for this important inhalation study. This order reflects the\ngrowing confidence in our ability to support complex preclinical inhalation\nresearch, including in vivo studies where understanding the biological\nresponse to inhaled compounds is critical”, says Manoush Masarrat, CEO of\nInhalation Sciences.\n\n \n\nThis disclosure contains information that Inhalation Sciences is obliged to\nmake public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The\ninformation was submitted for publication, through the agency of the contact\nperson, on May 18, 2026, at 10:10.\n\n \n\nFor more information, please contact:\nManoush Masarrat, CEO\nPhone: +46 (0) 73 628 9153\nE-mail: manoush.masarrat@inhalation.se\n\n \n\nAbout Inhalation Sciences Sweden AB (publ)\nInhalation Sciences is a cutting-edge Contract Research Organization (CRO)\nspecializing in inhalation drug development. Leveraging our proprietary\ntechnology platform, PreciseInhale®, we empower our clients to de-risk and\naccelerate their R&D pipelines by delivering high-resolution, predictive data\nearly in the development process.\n\n \n\nhttps://news.cision.com/inhalation-sciences/r/inhalation-sciences-receives-irs-order-worth-approximately-eur-117-000%2Cc4349479\n\nInhalation Sciences receives IRS order worth approximately EUR 117000_PUB\n(https://mb.cision.com/Main/15842/4349479/4095629.pdf)\n\n\n\n(c) Copyright Waymaker BIT News - Cision 2026","article_body_html":"","raw_payload":{"data":{"id":"nWkr3xzwHF","title":"Inhalation Sciences receives IRS order worth approximately EUR 117,000","author":"Cision","ticker":"ISAB","created":"2026-05-18T08:10:09.079Z","tickers":["ISAB"],"exchange":"","article_body":"Inhalation Sciences\nInhalation Sciences Sweden AB (ISAB) today announces that it has received an\nIRS (Inhalation Research Services) order valued at approximately EUR 117,000\n(approximately SEK 1.3 million) from a new customer.\n\nThe customer is a European-based pharmaceutical and biotechnology company with\nextensive experience in producing both generic and innovative medicines.\n\nISAB will use its PreciseInhale® platform technology to generate high-quality\npreclinical study data. The study will involve in vivo testing - meaning the\nresearch is conducted in living organisms - to evaluate how the inhaled\ncompound behaves under real biological conditions.\n\n\"We are pleased that such a leading pharmaceutical company has chosen to\npartner with us for this important inhalation study. This order reflects the\ngrowing confidence in our ability to support complex preclinical inhalation\nresearch, including in vivo studies where understanding the biological\nresponse to inhaled compounds is critical”, says Manoush Masarrat, CEO of\nInhalation Sciences.\n\n \n\nThis disclosure contains information that Inhalation Sciences is obliged to\nmake public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The\ninformation was submitted for publication, through the agency of the contact\nperson, on May 18, 2026, at 10:10.\n\n \n\nFor more information, please contact:\nManoush Masarrat, CEO\nPhone: +46 (0) 73 628 9153\nE-mail: manoush.masarrat@inhalation.se\n\n \n\nAbout Inhalation Sciences Sweden AB (publ)\nInhalation Sciences is a cutting-edge Contract Research Organization (CRO)\nspecializing in inhalation drug development. Leveraging our proprietary\ntechnology platform, PreciseInhale®, we empower our clients to de-risk and\naccelerate their R&D pipelines by delivering high-resolution, predictive data\nearly in the development process.\n\n \n\nhttps://news.cision.com/inhalation-sciences/r/inhalation-sciences-receives-irs-order-worth-approximately-eur-117-000%2Cc4349479\n\nInhalation Sciences receives IRS order worth approximately EUR 117000_PUB\n(https://mb.cision.com/Main/15842/4349479/4095629.pdf)\n\n\n\n(c) Copyright Waymaker BIT News - Cision 2026"},"type":"article","timestamp":"2026-05-18T08:10:09.146712888Z","server_sent_at_ms":1779091809146},"received_at":"2026-05-18T08:10:09.204Z","source_url":"https://news.cision.com/inhalation-sciences/r/inhalation-sciences-receives-irs-order-worth-approximately-eur-117-000%2Cc4349479"},"analysis":{"id":"26835","press_release_id":"37392","analysis_json":{"industry":{"label":"Life Sciences Tools & Services","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Inhalation Sciences announced a new contract worth approximately EUR 117,000 (SEK 1.3 million) from a European pharmaceutical and biotechnology company.\n\nThe order involves using the company's PreciseInhale platform to generate preclinical study data, including in vivo testing of inhaled compounds.\n\nCEO Manoush Masarrat stated the deal reflects growing confidence in the company's ability to support complex preclinical inhalation research.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Small contract win validates CRO platform, but value is immaterial."},"keyFigures":{"customDimensions":{"contract_value_eur":117000,"contract_value_sek":1300000}},"quotedText":"We are pleased that such a leading pharmaceutical company has chosen to partner with us for this important inhalation study.","namedEntities":{"people":[{"name":"Manoush Masarrat","role":"CEO"}],"products":["PreciseInhale"],"companies":[{"name":"Inhalation Sciences Sweden AB","ticker":"ISAB"},{"name":"Inhalation Research Services","relationship":"subsidiary/service unit"}],"dollarAmounts":[{"amount":"EUR 117,000","context":"order value"},{"amount":"SEK 1.3 million","context":"order value in local currency"}]},"materialImpact":{"score":2,"reasoning":"A EUR 117k contract win is a positive operational milestone for a small-cap CRO, validating the PreciseInhale platform. However, the absolute value is too small to be material to the company's overall valuation or near-term financials."},"tickerRelevance":{"others":[],"primary":"ISAB"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"small-contract-win","sectorWeight":"biotech-cro","marketCapAdjustment":"low"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Inhalation Sciences announced a new contract worth approximately EUR 117,000 (SEK 1.3 million) from a European pharmaceutical and biotechnology company.\n\nThe order involves using the company's PreciseInhale platform to generate preclinical study data, including in vivo testing of inhaled compounds.\n\nCEO Manoush Masarrat stated the deal reflects growing confidence in the company's ability to support complex preclinical inhalation research.","key_figures":{"customDimensions":{"contract_value_eur":117000,"contract_value_sek":1300000}},"named_entities":{"people":[{"name":"Manoush Masarrat","role":"CEO"}],"products":["PreciseInhale"],"companies":[{"name":"Inhalation Sciences Sweden AB","ticker":"ISAB"},{"name":"Inhalation Research Services","relationship":"subsidiary/service unit"}],"dollarAmounts":[{"amount":"EUR 117,000","context":"order value"},{"amount":"SEK 1.3 million","context":"order value in local currency"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-18T08:10:18.290Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"small-contract-win","sectorWeight":"biotech-cro","marketCapAdjustment":"low"}},"durationMs":9082,"modelName":"george-droid-qwen-72b"}}